Risk of cancer among HIV-infected patients from a population-based nested case–control study: implications for cancer prevention

BMC Cancer

Chang-Hua Chen³  Chih-Yuan Chung⁵  Li-Hsuan Wang¹  Che Lin²  Hsiu-Li Lin⁶  Hsiu-Chen Lin⁴ 

[1] School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

[2] Department of Environmental Engineering, National Chung-Hsing University, Taichung, Taiwan

[3] College of Medicine & Nursing, Hung Kuang University, Taichung City, Taiwan

[4] Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei, Taiwan

[5] Division of Hematology and Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan

[6] Department of Neurology, General Cathay Hospital, Sijhih Branch, New Taipei City, Taiwan

关键词: Risk;    Taiwan;    Human immunodeficiency virus;    Cancer;   

Others  :  1143977
DOI  :  10.1186/s12885-015-1099-y

 received in 2014-06-17, accepted in 2015-02-20,  发布年份 2015

【 摘 要 】

Background

The burden of cancer is likely to increase among the human immunodeficiency virus (HIV)-positive population as it ages due to successful antiretroviral therapy (ART). The purpose of this study was to determine the risk of cancer in HIV-infected patients.

Methods

This study was a matched nested case–control study. It was performed using the National Health Insurance Research Database of Taiwan. The control group included non–HIV-infected patients matched by sex, age, and year of enrollment. Logistic regression analyses were performed and simultaneously adjusted for potential confounders (income, urbanization, and Charslon index of comorbidity to evaluate HIV infection as an independent risk of cancer. We calculated the overall and sex-specific standardized incidence ratios (SIR) to investigate the pattern of cancer risk and overall cancer risk in the patients with HIV infection.

Results

Of the 1,115 HIV-infected patients, 104 (9.33%) developed cancer during the 11-year follow-up period. The risk of cancer for patients with HIV infection was significant (adjusted odds ratio = 3.89, 95% confidence interval [CI] = 2.92–5.19) after adjustment for potential confounders. There was a significantly increased risk of developing non-Hodgkin lymphoma (SIR = 25.73, 95% CI = 6.83-90.85), cervical cancer (SIR = 4.01, 95% CI = 1.0-16.06), lymphoma (SIR = 20.26, 95% CI = 5.86-70.10), and respiratory and intrathoracic cancer (SIR = 20.09, 95% CI = 2.34-172.09) compared with the control group. In addition, HIV-infected patients were at significant risk for renal, oral, breast, liver, skin, and colorectal cancer.

Conclusions

Patients with HIV infection are at increased risk for several specific cancers. Our results support the implementation of an active and accelerated cancer screening schedule for patients with HIV infection to increase their life span.

【 授权许可】

   
2015 Chen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, et al.: Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an Italian multicenter study. PLoS One 2014, 9:e94768.
• [2]Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, et al.: Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet 1981, 8:598-600.
• [3]Curran JW, Jaffe HW: AIDS: the early years and CDC’s response. MMWR Surveill Summ 2011, 8:64-9.
• [4]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.: WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens–Part B: biological agents. Lancet Oncol 2009, 8:321-2.
• [5]Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al.: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998, 280:497-503.
• [6]Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al.: Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014, 384:241-8.
• [7]Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, et al.: Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006, 4:1-22.
• [8]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-83.
• [9]Cooley TP: Non–AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin North Am 2003, 17:889-99.
• [10]Intra M, Gentilini O, Brenelli F, Chagas EM, Veronesi U, Sandri MT: Breast cancer among HIV infected patients: the experience of the European Institute of Oncology. J Surg Oncol 2005, 91:141-2.
• [11]Goedert JJ, Schairer C, McNeel TS, Hessol NA, Rabkin CS: Engels EA; HIV/AIDS Cancer Match Study: HIV/AIDS Cancer Match Study, Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer 2006, 95:642-8.
• [12]Shiels MS, Cole SR, Kirk GD, Poole C: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009, 52:611-22.
• [13]Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A: Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep 2011, 8:142-52.
• [14]Simard EP, Engels EA: Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010, 51:957-62.
• [15]Shiels MS, Pfeiffer RM, Engels EA: Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010, 153:452-60.
• [16]Vogel M, Friedrich O, Lüchters G, Holleczek B, Wasmuth JC, Anadol E, et al.: Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence. Eur J Med Res 2011, 16:101-7. BioMed Central Full Text
• [17]Biggar RJ, Chaturvedi AK, Goedert JJ: Engels EA; HIV/AIDS Cancer Match Study: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007, 99:962-72.
• [18]Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, et al.: Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 2009, 18:1807-14.
• [19]Taiwan Breast Cancer Foundation: Current status of breast cancer in Taiwan. http://www.breastcf.org.tw/index.php/knowledge-base/current-status.
• [20]Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, Chen DR: Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 2009, 9:192. BioMed Central Full Text
• [21]Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM: Decreasing rates of Kaposi’s sarcoma and non-Hodgkin’s lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001, 15:629-33.
• [22]Crum-Cianflone N, Hullsiek KH, Satter E, Marconi V, Weintrob A, Ganesan A, et al.: Cutaneous malignancies among HIV-infected persons. Arch Intern Med 2009, 169:1130-8.
• [23]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics. CA Cancer J Clin 2005, 55:74.
• [24]Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al.: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011, 103:753-62.
• [25]Mani D, Haigentz M Jr, Aboulafia DM: Lung cancer in HIV infection. Clin Lung Cancer 2012, 13:6-13.
• [26]Clifford GM, Lise M, Franceschi S, Egger M, Bouchardy C, Korol D, et al.: Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012, 106:447-52.
• [27]Bureau of Health Promotion, D.O.H., Taiwan, ROC: Cancer Registry Annual Report, 1995–2008. Department of Health, Executive Yuan, Taiwan, ROC, Taipei; 2010.
• [28]Warnakulasuriya S: Causes of oral cancer–an appraisal of controversies. Br Dent J 2009, 207:471-5.
• [29]Palefsky J: Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007, 15:130-3.
• [30]Chaiyachati K, Cinti SK, Kauffman CA, Riddell J: HIV-infected patients with anal carcinoma who subsequently developed oral squamous cell carcinoma: report of 2 cases. Int Assoc Physicians AIDS Care (Chic) 2008, 7:306-10.
• [31]Guidleine for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents in 2014. http://aidsinfo.nih.gov/guidelines.
• [32]Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L: Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer 2009, 8:215-9.
• [33]Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-50.
• [34]Bodaghi S, Yamanegi K, Xiao SY, Da Costa M, Palefsky JM, Zheng ZM: Colorectal papillomavirus infection in patients with colorectal cancer. Clin Cancer Res 2005, 11:2862-7.
• [35]Dalgleish AG, O’Byrne KJ: Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 2002, 84:231-6.
• [36]Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492-7.
• [37]Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group Hepatology 1999, 30:1054-8.
• [38]Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, et al.: Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006, 44:47-55.
• [39]Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al.: HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009, 23:2337-45.